Camilla TÃ¸ndel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8803295/publications.pdf

Version: 2024-02-01

43 papers	2,137 citations	361413 20 h-index	315739 38 g-index
45 all docs	45 docs citations	45 times ranked	2531 citing authors

#	Article	IF	Citations
1	Randomised controlled trial showed longâ€term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children. Acta Paediatrica, International Journal of Paediatrics, 2022, 111, 391-400.	1.5	3
2	Cardiovascular changes in young renal failure patients. CKJ: Clinical Kidney Journal, 2022, 15, 183-185.	2.9	0
3	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	4.2	3
4	Reduced Î±-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype. Molecular Genetics and Metabolism Reports, 2022, 31, 100851.	1.1	6
5	A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease. Kidney International, 2022, 102, 173-182.	5.2	3
6	Measurement of renal functional response using iohexol clearanceâ€"a study of different outpatient procedures. CKJ: Clinical Kidney Journal, 2021, 14, 181-188.	2.9	1
7	SARS-CoV-2â€"Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. Journal of Infectious Diseases, 2021, 223, 589-599.	4.0	31
8	Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age. Pediatric Infectious Disease Journal, 2021, 40, 317-323.	2.0	9
9	Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. Lancet Regional Health - Europe, The, 2021, 3, 100014.	5.6	39
10	MO127CLEARED PODOCYTES AND NORMAL KIDNEY FUNCTION IN CLASSICAL FABRY MALES 15 YEARS AFTER START OF ENZYME REPLACEMENT THERAPY AT YOUNG AGE*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
11	Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An openâ€label, phase 3, doseâ€titration study. Neurourology and Urodynamics, 2021, 40, 1490-1499.	1.5	15
12	Long COVID in a prospective cohort of home-isolated patients. Nature Medicine, 2021, 27, 1607-1613.	30.7	453
13	Low birthweight is associated with lower glomerular filtration rate in middle-aged mainly healthy women. Nephrology Dialysis Transplantation, 2021, 37, 92-99.	0.7	6
14	Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis. Blood, 2021, 138, 516-516.	1.4	4
15	Accuracy of single intravenous access iohexol GFR in children is hampered by marker contamination. Scientific Reports, 2021, 11, 23224.	3.3	0
16	1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial. Open Forum Infectious Diseases, 2021, 8, S671-S671.	0.9	3
17	The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic modelâ€"based pediatric dose estimation. Journal of Pediatric Urology, 2020, 16, 31.e1-31.e10.	1.1	9
18	Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation. Disease Markers, 2020, 2020, 1-8.	1.3	15

#	Article	IF	Citations
19	The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease â€“ A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism, 2019, 126, 212-223.	1.1	50
20	SP035CLINICAL CONSEQUENCES OF PAIRED CARDIAC AND KIDNEY BIOPSIES IN A TREATMENT NAÃVE FEMALE FABRY PATIENT WITH A CLASSICAL MUTATION AND MINOR CLINICAL SYMPTOMS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
21	Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial. Molecular Genetics and Metabolism, 2019, 127, 86-94.	1.1	25
22	Estimating glomerular filtration rate in children: evaluation of creatinine- and cystatin C-based equations. Pediatric Nephrology, 2019, 34, 301-311.	1.7	23
23	Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. Pediatric Nephrology, 2018, 33, 683-696.	1.7	16
24	FP771IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR. Nephrology Dialysis Transplantation, 2018, 33, i305-i306.	0.7	0
25	European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism, 2018, 124, 189-203.	1.1	122
26	Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrology Dialysis Transplantation, 2017, 32, gfw094.	0.7	34
27	Pathomechanisms of renal Fabry disease. Cell and Tissue Research, 2017, 369, 53-62.	2.9	27
28	Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1470-1479.	4.5	42
29	Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. Pediatric Nephrology, 2017, 32, 311-320.	1.7	21
30	Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinaseâ€“Associated Lipocalin in Children. journal of applied laboratory medicine, The, 2017, 2, 297-308.	1.3	5
31	MP042BENEFICIAL EFFECTS ON PODOCYTE GLOBOTRIAOSYLCERAMIDE DEPOSITS IN SERIAL KIDNEY BIOPSIES OF FABRY CHILDREN AND ADULTS AFTER UP TO 13 YEARS OF ENZYME REPLACEMENT. Nephrology Dialysis Transplantation, 2016, 31, i356-i356.	0.7	0
32	One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. PLoS ONE, 2016, 11, e0152812.	2.5	38
33	Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis. Molecular Genetics and Metabolism, 2015, 114, 242-247.	1.1	51
34	Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet Journal of Rare Diseases, 2015, 10, 36.	2.7	239
35	Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial. PLoS ONE, 2015, 10, e0124987.	2.5	42
36	Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 710-6.	1.2	11

#	Article	IF	Citations
37	Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease. PLoS ONE, 2014, 9, e112188.	2.5	29
38	Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. Journal of the American Society of Nephrology: JASN, 2013, 24, 137-148.	6.1	202
39	Safety and Complications of Percutaneous Kidney Biopsies in 715 Children and 8573 Adults in Norway 1988â€“2010. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1591-1597.	4.5	206
40	Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney International, 2011, 79, 663-670.	5.2	138
41	Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. Nephrology Dialysis Transplantation, 2010, 25, 1507-1513.	0.7	31
42	Renal Biopsy Findings in Children and Adolescents With Fabry Disease and Minimal Albuminuria. American Journal of Kidney Diseases, 2008, 51, 767-776.	1.9	173
43	Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with fabry disease and microalbuminuria. Clinical Therapeutics, 2008, 30, S42.	2.5	6